Global Temporal Arteritis Market Growth 2025-2031
Description
The global Temporal Arteritis market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Temporal arteritis is also known as Horton"s arteritis and is considered to be a severe form of vasculitis which means inflammation of the blood vessels. It is a potentially life-threatening inflammatory condition of the arteries. It can cause scalp tenderness and headaches. This condition usually occurs in temporal arteries and may occur in any medium to large artery of the body. As this condition generally occurs in aged population, it is also known as arteritis of the aged. Other names of temporal arteritis includes Horton disease, arteritis cranialis, and granulomatous arteritis.
United States market for Temporal Arteritis is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Temporal Arteritis is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Temporal Arteritis is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Temporal Arteritis players cover Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Temporal Arteritis Industry Forecast” looks at past sales and reviews total world Temporal Arteritis sales in 2024, providing a comprehensive analysis by region and market sector of projected Temporal Arteritis sales for 2025 through 2031. With Temporal Arteritis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Temporal Arteritis industry.
This Insight Report provides a comprehensive analysis of the global Temporal Arteritis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Temporal Arteritis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Temporal Arteritis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Temporal Arteritis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Temporal Arteritis.
This report presents a comprehensive overview, market shares, and growth opportunities of Temporal Arteritis market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Oral
Parenteral
Segmentation by Application:
Hospital
Home Care
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novartis AG
Endo International Inc
Teva Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Ltd
Cipla Inc
Dr Reddy's Laboratories Ltd
Abbott
F. Hoffmann -La Roche Ltd
Pfizer Inc
Zydus Group
Lupin
Amorphex Therapeutics Holdings, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Astellas Pharma Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Temporal Arteritis market?
What factors are driving Temporal Arteritis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Temporal Arteritis market opportunities vary by end market size?
How does Temporal Arteritis break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Temporal arteritis is also known as Horton"s arteritis and is considered to be a severe form of vasculitis which means inflammation of the blood vessels. It is a potentially life-threatening inflammatory condition of the arteries. It can cause scalp tenderness and headaches. This condition usually occurs in temporal arteries and may occur in any medium to large artery of the body. As this condition generally occurs in aged population, it is also known as arteritis of the aged. Other names of temporal arteritis includes Horton disease, arteritis cranialis, and granulomatous arteritis.
United States market for Temporal Arteritis is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Temporal Arteritis is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Temporal Arteritis is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Temporal Arteritis players cover Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Temporal Arteritis Industry Forecast” looks at past sales and reviews total world Temporal Arteritis sales in 2024, providing a comprehensive analysis by region and market sector of projected Temporal Arteritis sales for 2025 through 2031. With Temporal Arteritis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Temporal Arteritis industry.
This Insight Report provides a comprehensive analysis of the global Temporal Arteritis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Temporal Arteritis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Temporal Arteritis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Temporal Arteritis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Temporal Arteritis.
This report presents a comprehensive overview, market shares, and growth opportunities of Temporal Arteritis market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Oral
Parenteral
Segmentation by Application:
Hospital
Home Care
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novartis AG
Endo International Inc
Teva Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Ltd
Cipla Inc
Dr Reddy's Laboratories Ltd
Abbott
F. Hoffmann -La Roche Ltd
Pfizer Inc
Zydus Group
Lupin
Amorphex Therapeutics Holdings, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Astellas Pharma Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Temporal Arteritis market?
What factors are driving Temporal Arteritis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Temporal Arteritis market opportunities vary by end market size?
How does Temporal Arteritis break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
106 Pages
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Temporal Arteritis by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Temporal Arteritis by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
